BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34028782)

  • 1. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
    Wang K; Li Y; Wang J; Chen R; Li J
    Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
    Huang G; Zhang J; Gong L; Huang Y; Liu D
    BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
    Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
    J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
    Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
    Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.
    He R; Zuo S
    Front Oncol; 2019; 9():693. PubMed ID: 31417870
    [No Abstract]   [Full Text] [Related]  

  • 12. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
    BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
    Noro R; Ishigame T; Walsh N; Shiraishi K; Robles AI; Ryan BM; Schetter AJ; Bowman ED; Welsh JA; Seike M; Gemma A; Skaug V; Mollerup S; Haugen A; Yokota J; Kohno T; Harris CC
    J Thorac Oncol; 2017 Jan; 12(1):65-76. PubMed ID: 27613525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma.
    Zhai W; Chen S; Duan F; Wang J; Zhao Z; Lin Y; Rao B; Wang Y; Zheng L; Long H
    Cancer Med; 2023 Feb; 12(4):4968-4980. PubMed ID: 36056909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight-gene signature predicts recurrence in lung adenocarcinoma.
    Zhang Y; Fan Q; Guo Y; Zhu K
    Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
    Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
    J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma.
    Lee N; Xia X; Meng H; Zhu W; Wang X; Zhang T; Zhang C; Zhang J; Luo P
    Cancer Biomark; 2021; 30(1):63-73. PubMed ID: 32924987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.